Clinical and economic considerations of antiobesity treatment: A review of orlistat

ClinicoEconomics and Outcomes Research

Volumn 2, Issue 1, 2010, Pages 63-74

  Zohrabian, Armineh ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost effectiveness; Obesity; Orlistat; Weight loss

Indexed keywords

PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CHILD CARE; CHOLELITHIASIS; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE COMPARISON; EXERCISE; HEALTH ECONOMICS; HEPATITIS; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; LIFESTYLE MODIFICATION; LIVER FAILURE; LOW FAT DIET; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK REDUCTION; STEATORRHEA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77955433064     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s5101     Document Type: Review

References (114)

1. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2002;1-190. 2.
2. US National Center for Health Statistics. Table 75: Overweight, obesity, and healthy weight among persons 20 years of age and over, by selected characteristics: 1960-1962 through 2003-2006. In: Health, United States, 2008. Hyattsville, MD: US Department of Health and Human Services; 2009.
3. US National Center for Health Statistics. Table 76: Overweight among children and adolescents 6-19 years of age, by selected characteristics: 1963-1965 through 2003-2006. In: Health, United States, 2008. Hyattsville, MD: US Department of Health and Human Services; 2009.
4. Tjepkema M. Adult Obesity in Canada: measured height and weight. (Report No. 82-620-MWE.) Ottawa: Statistics Canada; 2005.
5. Rabin BA, Boehmer TK, Brownson RC. Cross-national comparison of environmental and policy correlates of obesity in Europe. Eur J Public Health. 2007;17:53-61.
6. Wu Y. Overweight and obesity in China. BMJ. 2006;333:362-363.
7. WHO/Europe. The challenge of obesity in the WHO European Region. Fact Sheet Euro/13/05. Copenhagen, Bucharest, 2005 Sep 12. Available at: http://www.euro.who.int/document/mediacentre/fs1305e.pdf. Accessed July 2009.
8. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238-1245.
9. Mokdad AH, Marks JS, Stroup DF, Geberding JL. Correction: Actual causes of death in the United States, 2000. JAMA. 2005;293: 293-294.
10. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-2212.
11. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res. 1995;3 Suppl 2:S211-S216.
12. Goldstein DJ. Beneficial effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
13. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-328.
14. Wing R, Jeffery RW. Effect of modest weight loss on changes in cardiovascular risk factors: are there differences between men and women or between weight loss and maintenance? Int J Obes Relat Metab Disord. 1995;19:67-73.
15. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23:1499-1504.
16. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9 Suppl 4: S326-S334.
17. Singh RB, Rastogi SS, Verma R, et al. Randomized controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow-up. BMJ. 1992;304:1015-1019.
18. Glazer G. Long-term pharmacotherapy of obesity 2000. A review of efficacy and safety. Arch Intern Med. 2001;161:1814-1824.
19. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Affairs. 2009;28:w822-w831.
20. Bhattacharya J, Sood N. Health insurance and the obesity externality. National Bureau of Economic Research Working Paper (No. 11529). Cambridge, MA: National Bureau of Economic Research; 2005. Available at: http://www.nber.org/papers/w11529. Accessed May 2009.
21. Idelevich E, Kirch W, Schindler C. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis. 2009;3:75-90.
22. Hartmann D, Hussain Y, Guzelhan C, Odink J. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmac. 1993;36:266-270.
23. UK National Institute for Health and Clinical Excellence. Obesity: Guidance on the Prevention, Identification, Assessment And Management Of Overweight And Obesity In Adults And Children. London: December 2006. Available at http://www.nice.org.uk/CG043. Accessed September 2009.
24. US National Heart, Lung, And Blood Institute Obesity Education Initiative Expert Panel. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6:S51-S209.
25. Singapore Ministry of Health. Obesity. Singapore: Singapore Ministry of Health; April 2004.
26. US Department of Veterans Affairs, Department of Defense (VA/DoD). VA/DoD Clinical Practice Guideline for Screening and Management of Overweight and Obesity. Washington D.C.: US Department of Veterans Affairs, Department of Defense; 2006.
27. American College of Physicians (ACP). Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142:525-531.
28. US National Guideline Clearinghouse. Guideline synthesis: assessment and treatment of obesity and overweight in adults. In: National Guideline Clearinghouse [website]. Rockville (MD): 2005 Apr 18 (revised 2009 Jan). Available at http://www.guideline.gov. Accessed September 2009.
29. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004096. DOI:10.1002/14651858.CD004096.pub2.
30. US National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-1915.
31. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENICAL in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
32. Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev. 2008;9:420-427.
33. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J. 2007;335:1194-1199.
34. Li ZP, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
35. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8:iii-182.
36. Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq Bras Endocrinol Metab. 2009;53:262-270.
37. Douketis JD, Macie C, Thabane L, Willamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes. 2005;29: 1153-1167.
38. Wing RR. Weight loss in the management of type 2 diabetes. In: Gerstein HC, Haynes RB, editors. Evidence-Based Diabetes Care. Ontario, Canada: B.C. Decker, Inc; 2000:252-276.
39. Greenway F, Heber D, Raum W, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res. 1999;7:370-378.
40. Rege S. Antipsychotic-induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry. 2008;42:369-381.
41. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71-77.
42. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30:27-32.
43. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13:123-136.
44. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev. 2000;1:113-119.
45. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res. 2004;12(Suppl):S151-S162.
46. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995;141:1128-1141.
47. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol. 1999;149: 491-503.
48. Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med. 2004;21:403-414.
49. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ. 2007;334:299.
50. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
51. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:977-986.
52. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 1998;25:1033-1041.
53. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25:1123-1128.
54. Law MR, Walk NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372.
55. Sharma AM, Bramlage P, Kirch W. Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study. Clin Drug Investig. 2005;25:765-776.
56. Siebenhofer A, Horvath K, Jeitler K, et al. Long-term effects of weightreducing drugs in hypertensive patients. Cochrane Library Issue 2; 2009. Available at http://www.thecochranelibrary.com. Accessed September 2009.
57. Douketis JD, Sharma AM. The management of hypertension in the overweight and obese patient - is weight reduction sufficient? Drugs. 2004;64:795-803.
58. Horvath K, Jeitler K, Siering U, et al. Long-term effects of weightreducing interventions in hypertensive patients: Systematic review and meta-analysis. Arch Intern Med. 2008;168:571-580.
59. Mannucci E, Dicembrini I, Rotella F, Rotella CM. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis. 2008;18: 342-348.
60. Hsieh C-J, Wang P-W, Liu R-T, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract. 2005;67:78-83.
61. Chan KW, Leung WS, Fung YS, et al. The effects of diet and orlistat on body weight and lipid profiles in high risk Chinese patients with coronary artery disease, obesity and hypercholesterolemia. Ir J Med Sci. 2009;178:173-178.
62. Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism. 2009;58:946-953.
63. Eriksson KF, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with Diet and exercise. Diabetologia. 1998;41: 1010-1016.
64. Yaari S, Goldbourt U. Voluntary and involuntary weight loss: associations with long-term mortality in 9,228 middle-aged and elderly men. Am J Epidemiol. 1998;148:546-555.
65. Diehr P, Bild DE, Harris TB, Duxbury A, Siscovick D, Rossi M. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health. 1998;88:623-629.
66. French SA, Folsom AR, Jeffery RW, Williamson DF. Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study. Am J Epidemiol. 1999;149: 504-514.
67. Gregg E, Gerzoff RB, Thompson TJ, Williamson DF. Intentional weight loss and death in overweight and obese US adults 35 years of age and older. Ann Intern Med. 2003;138:383-389.
68. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. JAMA. 1999;281:235-242.
69. Svendsen M, Helgeland M, Tonstad S. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. J Hum Nutr Diet. 2009;22:55-63.
70. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety. 2008;31:53-65.
71. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Expert Opin Drug Safe. 2008;7:147-158.
72. Willemen MJ, Mantel-Teeuwisse AK, Straus SMJM, Leufkens HGM, Egberts ACG, Sturkenboom MCJM. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs. Pharmacoepidemiol Drug Safe. 2009;7:631-638.
73. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring). 2007;15(11):2712-2722.
74. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10:333-341.
75. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567-1570.
76. Phelan S, Wadden TA. Combining behavioral and pharmacological treatments for obesity. Obes Res. 2002;10:560-574.
77. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. NEJM. 2005;353:2111-2120.
78. Blanck HM, Kettel Khan L, Serdula MK. Diet and physical activity behavior among users of prescription weight loss medications. Int J Behav Nutr Phys Act. 2004;I:17. Available at: http://www.ijbnpa.org/content/I/I/17. Accessed October 2009.
79. Jay M, Kalet A, Ark T, et al. Physicians' attitudes about obesity and their associations with competency and specialty: A cross-sectional study. BMC Health Serv Res. 2009:9:106. Available at http://www.biomedcentral.com/1472-6963/9/106. Accessed Mar 10, 2010.
80. Green LA, Fryer GEJ, Yawn BP, Lanier D, Dovey SM. The ecology of medical care revisited. N Engl J Med. 2001;344:2021-2025.
81. Bowerman S, Bellman M, Saltsman P, et al. Implementation of a primary care physician network obesity management program. Obes Res. 2001;9 Suppl 4:S321-S325.
82. Galuska DA, Will JC, Serdula MK. Are health care professionals advising obese patients to lose weight? JAMA. 1999;282:1576-1578.
83. Sciamanna CN, Tate DF, Lang W, Wing RR. Who reports receiving advice to lose weight? Results from a multi-state survey. Arch Int Med. 2000;160:2334-2339.
84. Thande NK, Hurstak EE, Sciacca RE, Giardina EGV. Management of obesity: a challenge for medical training and practice. Obesity. 2008;17:107-113.
85. Phelan S, Nallari M, Darroch F, Wing RR. What do physicians recommend to their overweight and obese patients? J Am Board Fam Med. 2009;22:115-122.
86. Foster GD, Wadden TA, Makris AP, et al. Primary care physicians' attitudes about obesity and its treatment. Obes Res. 2003;11: 1168-1177.
87. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol. 1997;65:79-85.
88. Foster GD, Wadden TA, Phelan S, Sarwer DB, Sanderson RS. Obese patients' perceptions of treatment outcomes and the factors that influence them. Arch Intern Med. 2001;161:2133-2139.
89. Arnold M. GSK's launch of Alli is heavy on lifestyle messages. Med Mark Media. 2007;42:7.
90. Ippolito P, Pappalardo J. Advertising nutrition and health: evidence from food advertising, 1977-1997. Bureau of Economics Staff Report. Washington DC: Federal Trade Commission; 2002 Sept.
91. Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes. 2008;32: 1752-1763.
92. Maetzel A, Ruof J, Covington M, Wolf A. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics. 2003;21:501-512.
93. Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin. 2008; 24:63-74.
94. van Baal PHM, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health. 2008;11:1033-1040.
95. Roux L, Kuntz KM, Donaldson C, et al. Economic evaluation of weight loss interventions in overweight and obese women. Obesity. 2006:14;1093-1105.
96. Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. Obes Rev. 2005;6:323-328.
97. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev. 2000;1:121-126.
98. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med. 1992;327: 1350-1355.
99. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med. 1997;337:869-873.
100. Freedman DS, Kettle Khan L, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics. 2001;108: 712-718.
101. Bray GA. Predicting obesity in adults from childhood and adolescent weight. Am J Clin Nutr. 2002;76:497-498.
102. Guo SS, Wu W, Chumlea WC, Roche AF. Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am J Clin Nutr. 2002:76:653-658.
103. van Dam RM, Willett WC, Manson JE, Hu FB. The relationship between overweight in adolescence and premature death in women. Ann Intern Med. 2006;145:91-97.
104. Caprio S, Fennoy I, et al. The Endocrine Society. Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:4576-4599.
105. American Heart Association. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation. 2005;111:1999-2012.
106. Dietz WH. What constitutes successful weight management in adolescents? Ann Intern Med. 2006;145:145-146.
107. Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database of Systematic Reviews. 2009, Issue 1. Art. No.: CD001872. DOI: 10.1002/14651858.CD001872.pub2.
108. McGovern L, Johnson JN, Paulo R, et al. Treatment of pediatric obesity: A systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab. 2008;93:4600-4605.
109. Shin L, Bregman H, Frasier J, Noyes N. An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. Harvard Rev Psychiatry. 2008;16:69-79.
110. Mayer MA, Hocht C, Puyo A, Taira C. Recent advances in obesity pharmacotherapy. Curr Clin Pharmacol. 2009;4:53-61.
111. Blood Pressure Lowering Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;355:1955-1964.
112. Warden SJ, Fuchs RK. Are "exercise pills" the answer to the growing problem of physical inactivity? Br J Sports Med. 2008;42: 862-863.
113. Hawley JA, Holloszy JO. Exercise: It's the real thing. Nutr Rev. 2009;67: 172-178.
114. Roux L, Pratt M, Tengs TO, et al. Cost Effectiveness of Community-Based Physical Activity Interventions. Am J Prev Med. 2008;35: 578-588.